“Biopharmaceutical Third Party Logistics (3PL) Market Worth $87.62 Billion in 2019”, says Visiongain report

19 December 2019
Pharma

Visiongain’s new report the Biopharmaceutical Third Party Logistics (3PL) Market Report 2019-2029 : Forecasts by Supply Chain (Cold Chain, Non-Cold Chain), by Service Service Type (Transportation {Air Freight , Sea Freight , Overland Transportation}, Warehousing and Storage, Others), plus analysis of leading companies indicates that the global Biopharmaceutical Third Party Logistics (3PL) market will attain $137 billion revenue by 2029.

Global Biopharmaceutical Third Party Logistics market is expected to grow on account of increasing sales of biopharmaceutical and growing demand for safe delivery services for temperature-sensitive biologics. The market is expected to grow at a healthy CAGR of 4.6% over the projected period. In addition, increased demand for safe storage and transport of temperature-sensitive biopharmaceutical products are anticipated to reinforce the market concentration of biopharmaceutical 3PL over the projected period.

Over the past few years, demand for transportation outsourcing services has risen considerably. Outsourcing transportation services have led to reduced significant overheads of giant pharmaceutical companies. In addition, large biopharmaceutical businesses either sign an agreement or outsource services to 3PL service suppliers to decrease general operating costs, resulting in reduced pharmaceutical product prices. This has elevated the demand for biopharmaceutical 3PL services among giant biopharmaceutical companies.

In 2019, the Asia Pacific Biopharmaceutical Third Party Logistics (3PL) market accounted for more than 30% of overall market share. Strong economic growth followed by increasing sales of biopharmaceutical products in India, Japan, China, and Singapore is expected to increase Biopharmaceutical Third Party Logistics (3PL) market penetration over the forecast period. Asia Pacific market is growing on account of the growing aging population, the rising number of diseases is demanding for biologics and pharmaceuticals and high presence of CRO’s in the region.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever